To Evaluate the Effect of Bacillus Subtilis Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults.

Bioagile Therapeutics Pvt. Ltd.

Status

Invitation-only

Conditions

Healthy Participants Study

Treatments

Other: Placebo

Dietary Supplement: Probiotics (Bacillus Subtilis)

Study type

Interventional

Funder types

Industry

Identifiers

NCT07377942

BSP-25-072

Details and patient eligibility

About

The goal of this clinical trial is to Assess Gut Health and Immunomodulatory Effects of Bacillus Subtilis based product in Healthy Adults The main question[s] it aims to answer are to assess the effects of Bacillus Subtilis on gut health in healthy adults by measuring changes in fecal calprotectin levels as a marker of intestinal inflammation, in comparison between the intervention and placebo group.

To assess the immunomodulatory effects of Bacillus-Subtilis by measuring changes in inflammatory and immune response markers, in comparison between the intervention and placebo group To confirm the safety and tolerability of the study product Bacillus Subtilis in the healthy study population during the intended use, with safety assessments conducted across both the intervention and placebo groups.

The primary and secondary outcomes are:

Primary Efficacy Outcome:

Change in fecal calprotectin levels from baseline to the end of the study, comparing the intervention and placebo groups.
Changes in immunological markers (IgA, IgG, IgM) between baseline and study completion, comparing the intervention and placebo groups.

Secondary Efficacy Outcome:

• Improvement in the patient related overall relief, assessed using Gut Health Status Questionnaire (GHSQ) and Immune status questionnaire (ISQ) score with comparative analysis between the two groups.

Participants will be asked to take the probiotics twice daily morning and evening after meals and record it in the subject diary.

Enrollment

46 estimated patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female, aged between 18 and 50 years.
Female participants are either not of childbearing potential, or females of childbearing potential agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
In good general health, as determined by medical history, laboratory analysis, and physical examination performed by the study physician.
Willing to provide fecal samples as per the study requirements.
Willing to participate voluntarily and provide written informed consent.

Exclusion criteria

Women who are pregnant or lactating.
Subjects who are taking Antibiotic treatment.
Subjects suffering from Gastrointestinal disease.
Subjects suffering from Diabetes.
Subjects suffering from Chronic/iatrogenic Immunodeficiency.
Subjects suffering from Abnormal blood pressure.
Subjects who are allergic to ingredients of the study Product.
Subjects who are Smoker or alcoholic.
Subjects who have participated prior in conflicting clinical trial or have participated in the trial over the last 3months.
Women who are pregnant, breastfeeding, or planning to become pregnant.
Daily use of supplements that contain probiotics or prebiotics within 30 days prior to screening or during study.
Subjects with medical conditions affecting immune status (e.g., rheumatoid arthritis, heart failure, hepatitis C, HIV) or taking medications that may impact the immune system, such as antibiotics, antimicrobials, or probiotic sachets.
Any surgical treatment within the previous three months or planned during the study.
Any subject, in the principal investigator's opinion, not considered suitable for enrolment.